EICHOR
● Completed
Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Condition: Immune Thrombocytopenia · Sponsor: Sobi, Inc.
About this study
A Phase 3b Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects with Immune Thrombocytopenia for ≥6 Months
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (62)
| Site 112 | Phoenix, Arizona, United States | — |
| Site 103 | Long Beach, California, United States | — |
| Site 119 | Orange, California, United States | — |
| Site 109 | Sacramento, California, United States | — |
| Site 101 | San Francisco, California, United States | — |
| Site 111 | Aurora, Colorado, United States | — |
| Site 120 | Wilmington, Delaware, United States | — |
| Site 117 | Gainesville, Florida, United States | — |
| Site 116 | Atlanta, Georgia, United States | — |
| Site 107 | Peoria, Illinois, United States | — |
| Site 104 | Boston, Massachusetts, United States | — |
| Site 105 | Minneapolis, Minnesota, United States | — |
+ 50 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04516967